Expanding the Performance Envelope of the Total Artificial Heart: Physiological Characterization, Development of a Heart Failure Model, And Evaluation Tool for Mechanical Circulatory Support Devices
Author
Crosby, Jessica ReneeIssue Date
2014Keywords
Heart Failure ModelMechanical Circulatory Support Devices
Mock Circulatory System
Pressure-Volume Loops
Total Artificial Heart
Biomedical Engineering
Heart Failure
Advisor
Slepian, Marvin J.
Metadata
Show full item recordPublisher
The University of Arizona.Rights
Copyright © is held by the author. Digital access to this material is made possible by the University Libraries, University of Arizona. Further transmission, reproduction or presentation (such as public display or performance) of protected items is prohibited except with permission of the author.Embargo
Release after 1-Jun-2015Abstract
Heart failure (HF) affects an estimated 5.8 million Americans, accounting for near 250,000 deaths each year. With shortages in available donor hearts, mechanical circulatory support (MCS) has emerged as a life-saving treatment for advanced stage HF. With growth in MCS use, a clinical and developmental need has emerged for a standard characterization and evaluation platform that may be utilized for inter-device comparison and system training. The goal of this research was to harness SynCardia's total artificial heart (TAH) to meet this need. We first sought to characterize the TAH in modern physiological terms - i.e. hemodynamics and pressure-volume loops. We then developed a model of HF using the TAH and mock circulatory system operating in a reduced output mode. We demonstrated that MCS devices could be incorporated and evaluated within the HF model. Finally, we characterized the operational envelope of SynCardia's Freedom (portable), Driver operating against varying loading conditions. Our results describe the hemodynamic envelope of the TAH. Uniquely, the TAH was found not to operate with time-varying elastance, to be insensitive to variations in afterload up to at least 135 mmHg mean aortic pressure, and exhibit Starling-like behavior. After transitioning the setup to mimic heart failure conditions, left atrial pressure and left ventricular pressure were noted to be elevated, aortic flow was reduced, sensitivity to afterload was increased, and Starling-like behavior was blunted, consistent with human heart failure. The system was then configured to allow ready addition of ventricular assist devices, which upon placement in the flow circuit resulted in restoration of hemodynamics to normal. Lastly, we demonstrated that the Freedom Driver is capable of overcoming systolic pressures of 200 mmHg as an upper driving limit. Understanding the physiology and hemodynamics of MCS devices is vital for proper use, future device development, and operator training. Characterization of the TAH affords insight into the functional parameters that govern artificial heart behavior providing perspective on differences compared to the human heart. The use of the system as a heart failure model has the potential to serve as a valuable research and teaching tool to foster safe MCS device use.Type
textElectronic Dissertation
Degree Name
Ph.D.Degree Level
doctoralDegree Program
Graduate CollegeBiomedical Engineering
Degree Grantor
University of ArizonaCollections
Related items
Showing items related by title, author, creator and subject.
-
THE INCIDENCE AND PREDICTORS OF POST-SURGICAL CONFUSION IN CARDIAC TRANSPLANT RECIPIENTS (POST-CARDIOTOMY DELERIUM, HEART TRANSPLANTATION, OPEN-HEART SURGERY).LeRoy, James Allan, 1955- (The University of Arizona., 1986)
-
Beta₃-adrenergic receptors in the heart: Normal functions and potential roles in heart failureRestifo, Linda L.; Salamanca, Melissa; Restifo, Linda L.; Doetschman, Thomas C.; Elliott, David A. (The University of Arizona., 2016)Heart Failure is the state in which the heart is unable to pump enough blood to meet the needs of the body, resulting from events that progressively damage the myocardium and/or its ability to contract normally. Several compensatory mechanisms allow for short-term maintenance of adequate delivery of blood to the body. Progression from the initial events to heart failure is caused by the accumulation of pathologic changes and their effects, many of which result from chronic activation of these compensatory mechanisms. One of these mechanisms is the activation of the neurohormonal β-adrenergic system, to which the β₃-adrenergic receptor (β₃-AR) belongs. Research on the role of the β₃-AR in the heart has focused on the short-term protective role of the receptor, based on its ability to reduce the effects of over-stimulation of the heart's other adrenergic-system components. However, during the course of heart failure, its up-regulation and functional persistence may also contribute to the progression of the disease. There have been few large-animal studies, no human trials, and no long-term studies of β₃-AR agonists for use in the treatment of heart failure. Ultimately, individualized treatment strategies that, over time, modulate the relative levels of agonistic and antagonistic effects across each of the three β₃-AR subtypes, may be most effective for management of heart failure. However, further research and trials with β₃-AR agonists are realistic and necessary places to start.
-
Matters of the Heart: Studying Heart Muscle CellsMcGinley, Susan (College of Agriculture and Life Sciences, University of Arizona (Tucson, AZ), 1995-11)